drugset / Trial / NCT03819010

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -

NCT03819010

Phase 2 Completed 66 enrolled MedSIR Pfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an international, multicenter, open-label, non-comparative, Simon´s two-stage design, phase II clinical trial.

Timeline

Start
2019-05-07
Primary completion
2019-07-30
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 2.5 mg
Comparator Palbociclib Small molecule 125 mg

Indications